Thursday 13 August 2020
Home      All news      Contact us      India
business-standard - 30 days ago

Cipla update on renegotiation for development commercialization of Pulmazole

Discussions to renegotiate the terms of the Agreement are now in progress. Due to the delays in patient enrolment for the Phase 2a clinical study managed by Pulmatrix, the Joint Steering Committee has terminated the Phase 2a clinical study in order to commence a new Phase 2b study with longer dose duration and efficacy endpoints, upon Agreement negotiations with Pulmatrix being successful. It s Cipla s position that under the terms of the Agreement it has the right to suspend additional funding under certain circumstances. The renegotiated agreement may include, amongst other things a reallocation of costs and a grant of rights to CipTec (and/or its affiliates) to develop and commercialize Pulmazole in select markets outside the United States. Updates on this amendment to the Agreement and other related developments will be provided in the future.

Latest News












Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)